In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Collaborating for Better R&D Productivity

Executive Summary

Pooling multiple pharmaceutical companies' assets across a given therapeutic area will allow industry to make rational R&D investment decisions, expedite resource allocation and reduce investment in also-rans, eventually boosting productivity and improving a worsening reimbursement environment. Oncology may be a smart place to begin.

You may also be interested in...



In A First, Merck And AstraZeneca Team Up For Oncology Study

The two Big Pharmas have allied for early development of Merck’s AKT inhibitor and AZ’s Mek inhibitor. But where do they go from there?

Best of the Blog: IN VIVO, May/June 2009

Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.

Best of the Blog: IN VIVO, May/June 2009

Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel